A 2.4-mg weekly injection of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide led to a clinically meaningful 5% loss in weight for roughly two thirds of patients with both overweight/obesity and type 2 diabetes, researchers report. These findings from the Semaglutide Treatment Effect in People With Obesity 2 (STEP 2) trial, one of four phase
Managing type 1diabetes during the first two decades of life is challenging. Insulin requirements change along with the stages of life —- childhood, puberty, young adulthood, and beyond. But a 20-year longitudinal study conducted by researchers from Joslin Diabetes Center and Harvard Medical School identifies clear predictors of rising A1C levels in young persons, as
(HealthDay)—There does not appear to be a clinically meaningful association between baseline or prospective hemoglobin A1c (A1C) and wound healing in patients with diabetic foot ulcers (DFUs), according to a study published online April 16 in Diabetes Care. Betiel K. Fesseha, M.D., from Johns Hopkins University in Baltimore, and colleagues retrospectively evaluated the association between
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok